All In Biotech

Drug Trial Radar · NCT06422923

A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Temporal Lobe Epilepsy (MTLE)

Last checked: Nov 19, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Nov 14, 2024

Primary completion

Jun 15, 2027

Study completion Jun 15, 2042

Sponsor

Lead sponsor
Neurona TherapeuticsIndustry
Sponsor type
Industry
First posted
May 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, single arm, open label clinical trial that is designed to test the safety and preliminary efficacy of single administration inhibitory nerve cells called interneurons (NRTX-1001), into both temporal lobes of subjects with drug-resistant bilateral mesial temporal lobe epilepsy.

Conditions

  • Epilepsy, Temporal Lobe

Interventions

  • NRTX-1001Biological

    Biological: NRTX-1001 is an inhibitory neural cell therapy investigational product. It is derived from a human stem cell line that has been converted into high-purity inhibitory interneurons that produce GABA. NRTX-1001 is intended to persist long-term and not require repeated administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Serious Adverse Events at end of month 12Time frame: 12 months after treatment

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas · Recruiting

  • University of Southern California Keck Hospital

    Los Angeles, California · Recruiting

  • UC Irvine Medical Center

    Orange, California · Recruiting

  • Stanford University

    Palo Alto, California · Recruiting

  • University of California San Diego

    San Diego, California · Recruiting

  • University of California San Francisco

    San Francisco, California · Withdrawn

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado · Recruiting

  • University of Chicago

    Chicago, Illinois · Recruiting

  • University of Iowa Health Care

    Iowa City, Iowa · Recruiting

  • SUNY Upstate Medical University

    Syracuse, New York · Recruiting

  • Atrium Health

    Charlotte, North Carolina · Recruiting

  • Duke University Hospital

    Durham, North Carolina · Recruiting

  • Wake Forest Baptist Medical Center

    Winston-Salem, North Carolina · Recruiting

  • Oregon Health and Science University

    Portland, Oregon · Recruiting

  • UTHealth Houston

    Houston, Texas · Recruiting

  • UVA Health University Medical Center

    Charlottesville, Virginia · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.